A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effect of Golimumab Administered Subcutaneously in Subjects With Active Axial Spondyloarthritis (Protocol No. P07642, Also Known as MK-8259-006-02)

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effect of Golimumab Administered Subcutaneously in Subjects With Active Axial Spondyloarthritis (Protocol No. P07642, Also Known as MK-8259-006-02)

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms GO-AHEAD
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 26 Jun 2015 According to an MSD media release, the European Commission approved SIMPONI (golimumab) following the positive opinion of the CHMP for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA) based on the findings from this GO-AHEAD study.
    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
    • 13 Jun 2015 Results assessing quality of life presented at the 16th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top